Publications

Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Volume 12 of Issue 10 Molecular cancer therapeutics. 2013. PMID: 23918833


Biran N, Jagannath S, Chari A. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clinical advances in hematology & oncology : H&O. 2013. PMID: 24518420


Hauer KE, Soni K, Cornett P, Kohlwes J, Hollander H, Ranji SR, Ten Cate O, Widera E, Calton B, O'Sullivan PS. Developing entrustable professional activities as the basis for assessment of competence in an internal medicine residency: a feasibility study. Journal of general internal medicine. 2013. PMID: 23595926


Van Loon K, Venook AP. Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park, N.Y.). 2013. PMID: 24133822


Van Loon K, Venook AP. Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park, N.Y.). 2013. PMID: 24133822


Mookherjee S, Pheatt L, Ranji SR, Chou CL. Physical examination education in graduate medical education--a systematic review of the literature. Journal of general internal medicine. 2013. PMID: 23568186


Calvin Chou, MD

Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ, Alliance for Clinical Trials in Oncology. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer. 2013. PMID: 23913744


Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ, Alliance for Clinical Trials in Oncology. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer. 2013. PMID: 23913744


Mereniuk TR, El Gendy MA, Mendes-Pereira AM, Lord CJ, Ghosh S, Foley E, Ashworth A, Weinfeld M. Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. Molecular cancer therapeutics. 2013. PMID: 23883586


Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. PMID: 23881923


Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British journal of cancer. 2013. PMID: 23880820


Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British journal of cancer. 2013. PMID: 23880820


Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Volume 62 of Issue 11 Diabetes. 2013. PMID: 23835333


Daud AI. Reply to M.-E. Percival et al and L.B. Saltz. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013. PMID: 23967490


Muralidhar KR, Komanduri K, Rout BK, Ramesh KK. Commissioning and quality assurance of Calypso four-dimensional target localization system in linear accelerator facility. Journal of medical physics. 2013. PMID: 24049322


Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013. PMID: 23816964